The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Boston Scientific Corporation (BSX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.20, or -0.44%, to $45.61. The Boston Scientific Corporation has recorded 634,605 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results.
Boston Scientific Corporation is listed on the NYSE as a member of the Healthcare sector and is a part of the Medical Devices industry. At the end of the last regular session, the stock closed at $45.81 and fluctuated between $46.19 as its day high and $44.35 as its day low. The current market capitalization of Boston Scientific Corporation is $64.81B. A total of 11.77 million shares were traded on the day, compared to an average of 6.82M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, BSX has seen 5 BUY and 11 SELL insider trades, representing the acquisition of 235,339 and the disposition of 313,377 shares. Over the last 12 months, there were 118 BUYs and 137 SELLs from insiders. Insiders purchased 1,004,314 shares during that period but sold 1,426,570.
In the most recent transaction, Mirviss Jeffrey B. sold 6,751 shares of BSX for 46.38 per share on Jan 04. After the transaction, the EVP&Pres, Periph Intervent now owns 88,479 company shares. In a previous transaction on Dec 15, Carruthers Wendy sold 7,500 shares at 46.62 per share. BSX shares that EVP, Human Resources owns now total 87,413.
Among the insiders who sold shares, Fitzgerald Joseph Michael disposed of 79,264 shares on Dec 13 at a per-share price of $47.78. This resulted in the EVP & Group Pres, Cardiology holding 216,871 shares of BSX after the transaction. In another insider transaction, Mirviss Jeffrey B. sold 11,080 shares at $46.75 per share on Dec 12. Company shares held by the EVP&Pres, Periph Intervent now total 88,479.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for BSX in the last 3 months, the mean price target is $51.12 with high estimates of $56.00 and low estimates of $45.00. In terms of 52-week highs and lows, BSX has a high of $47.95 and a low of $34.98.
As of this writing, BSX has an earnings estimate of $0.47 per share for the current quarter. EPS was calculated based on a consensus of 24 estimates, with a high estimate of $0.5 per share and a lower estimate of $0.45. The company reported an EPS of $0.44 in the last quarter, which was 4.80% higher than expectations of $0.42.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 29 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BSX is Sell with a score of 4.50. A total of 21 analysts rated the stock as Buy while 4 rated it as Overweight while 4 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.